ClinicalTrials.gg
Active, not recruitingNCT06791291KIBOU-T1DUpdated Nov 9, 2026

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

A Phase 2 interventional study of Teplizumab in Type 1 Diabetes Mellitus, sponsored by Sanofi. Active, not recruiting at 15 sites in Japan. Open to participants aged 1 Year to 34 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Nov 9, 2026Now Active, not recruitingEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
1 Year to 34 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.

Enrollment
11th of 11
5 · median 60
Started
2025
with 1 other
Phase 2
4 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
3 of 11
Sanofi

Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 11th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 9th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About teplizumab

teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 1 Year to 34 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing teplizumab in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.

Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA.

Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.

Read the detailed description

Total study duration is approximately 756 days.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
1 Year to 34 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Male or female Japanese participant, 1 (inclusive) to 34 years (inclusive) of age, at the time of signing the . Japanese: born in Japan or ethnic Japanese born outside of Japan, and a descendent of 4 ethnic Japanese grandparents who were all born in Japan.
  • Confirmed diagnosis of Stage 2 T1D based on following criteria:
  • Participant is positive for 2 or more T1D related auto-antibodies (confirmed by written medical history and/or obtained at study screening). The autoantibodies that are to be confirmed are anti-GAD (glutamic acid decarboxylase), anti-IA2 (insulinoma-associated antigen 2), anti-insulin, anti-ZnT8 (zinc transporter 8), and/or ICA (islet cell antibody).
  • Oral glucose tolerance test (OGTT) or blood confirms the participant has dysglycemia without overt hyperglycemia.
  • Participant must be in good health (except for being Stage 2 T1D) as determined by medical e)valuation including medical history, physical examination, laboratory tests, and (ECG) XE " ECG " \f Abbreviation \t "electrocardiogram" .
  • Participant is up to date with routine age-appropriate immunizations according to current local specific guideline prior to randomization.
  • Female participants should use consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • A female participant is considered fertile (woman of - WOCBP) from the time of menarche until becoming unless permanently sterile. Female participants are eligible to participate if one of the following conditions applies:
  • Is a woman of nonchildbearing potential (WONCBP) OR
  • Is a WOCBP and agrees to keep abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent, or use other highly effective contraceptive method, from signing of the informed consent to at least 3 months and 2 weeks after randomization and agrees not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction during this period.

A WOCBP must have at least a negative highly sensitive pregnancy test within 48 hours before the administration of study intervention.

If a urine test cannot be confirmed as negative (eg, an ambiguous result), a blood pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.

Participants are excluded from the study if any of the following criteria apply:

  • Any presence of cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic (except Stage 2 T1D), hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.
  • Participant has clinical signs and symptoms consistent with COVID19, eg, fever, dry cough, dyspnea, loss of taste and smell, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 4 weeks prior to Screening. Participant who had severe course of COVID-19 (ie, hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
  • For participant ≥18 years, blood donation of 400 mL within 12 weeks (male) or 16 weeks (female), 200 mL within 4 weeks or apheresis donation within 2 weeks before randomization; for participant \<18 years, blood donation of any volume within 16 weeks before randomization; for any participant, blood transfusion (any volume) within 2 months before randomization.
  • Presence or history of drug to any biologic medication, or clinically significant allergic disease as diagnosed and treated by a physician. Participants with known hypersensitivity to teplizumab or components of the teplizumab injection (including sodium phosphate, sodium chloride, polysorbate 80).
  • Participants with a history of active or latent or inactive tuberculosis (TB), including chest X-ray consistent with TB, regardless of treatment, or have a positive QuantiFERON-TB Gold test or T-SPOT TB test at screening.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with Epstein Barr virus (EBV), or history of infectious mononucleosis within 3 months before enrollment.
  • At screening, participant has laboratory or clinical evidence of acute or clinically active infection with cytomegalovirus (CMV).
  • Participants with a history of invasive opportunistic infections, such as histoplasmosis, listeriosis, coccidioidomycosis, candidiasis, pneumocystis jirovecii, aspergillosis, irrespective of resolution.
  • Participants have other diseases, except clinically stable autoimmune thyroid disease, or celiac disease.
  • Participants with a history of occurring within 5 years before randomization (except successfully treated carcinoma in situ of the cervix, or adequately treated nonmetastatic squamous cell or basal cell carcinoma of the skin).
  • Participants with fever (temperature ≥38.0°C) within 48 hours before randomization; or with chronic persistent or recurring infection(s) requiring active treatment with antibiotics, antiviral or antifungals within 4 weeks before randomization; or with other frequent recurrent infections deemed unacceptable as per Investigator's judgement.
  • If female, pregnancy (defined as positive blood or urine pregnancy test) or breast-feeding.
  • Participant has recent or planned vaccinations as follows:
  • : within 8 weeks before randomization, and/or within 54 weeks after randomization.
  • Non-live vaccines: any initial non-live vaccination within 2 weeks before randomization, and/or within 8 weeks after randomization.
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to cause a significant, ongoing change in the course of T1D or immunologic status, including high dose, inhaled, extensive topical, or systemic .
  • Participant has a current or prior (within 30 days before randomization) treatment that is known to significantly influence glucose tolerance (anti-hyperglycemic agents, atypical antipsychotics, diphenylhydantoin, niacin etc.).
  • Participant has received any anti-CD3 (cluster of differentiation 3) antibody treatment (including teplizumab) before randomization.
  • Participant who has received any biologic therapy within five half-lives of the therapy or within 6 months before randomization whichever is longer, or plan to receive any biologic therapy within 6 weeks after randomization.
  • Any participant enrolled or having participated, in this or any other clinical study involving an medicinal product (IMP) or in any other type of medical research and is still in the exclusion period according to applicable regulations (eg, having received an IMP of new active pharmaceutical ingredient (API) within 4 months or that of an approved API within 3 months before the administration of this study's IMP).
  • Participant has any of the following hematologic parameters before randomization:
  • Lymphocyte count \<1.0 ×109/L.
  • \<1.5 ×109/L.
  • count \<150 ×109/L.
  • \<100 g/L.
  • Participant has any of the following liver function test abnormalities before randomization:
  • >2 × (upper limit normal).
  • ALT >2 × ULN.
  • Total >1.5 × ULN with the exception of participants with the diagnosis of Gilbert's syndrome who may be eligible provided they have no other causes leading to hyperbilirubinemia.
  • Positive result on any of the following tests:
  • surface antigen or hepatitis B core antibody confirmed by positive HBV-DNA (hepatitis B virus DNA).
  • Anti- virus antibody confirmed by positive HCV-RNA (hepatitis C virus RNA).
  • antigen/ antibodies.
  • Positive SARS-CoV-2 test.
  • Participant who has or known allergy to both nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, or anti-histamines and in the opinion of the Investigator, cannot participate in the study.
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Teplizumab

    Participants will receive Teplizumab via IV infusion

    Drug: Teplizumab

  • No intervention
    Control

    Participants will receive no treatment in the control group

Interventions

  • Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

    Also known as: SAR446681, TZIELD

06

What researchers measure

Primary outcomes

  1. Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteria

    Time frame: From baseline up to Week 104

  2. Change from baseline in area under the curve (AUC) of C-peptide

    Time frame: From baseline up to Week 104

  3. Change from baseline in AUC of endogenous insulin

    Time frame: From baseline up to Week 104

  4. Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test

    TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event

    Time frame: Throughout the study, approximately 756 days

Secondary outcomes

  1. Change from baseline in fasting plasma glucose (FPG) from an oral glucose tolerance test

    Time frame: From baseline up to Week 104

  2. Change from baseline in 2-hour plasma glucose from an oral glucose tolerance test

    Time frame: From baseline up to Week 104

  3. Change from baseline of hemoglobin A1c (HbA1c)

    Time frame: From baseline up to Week 104

  4. Serum concentration of teplizumab

    Time frame: From Day 1 to Day 28

  5. Number of participants with anti-drug antibodies

    Time frame: From baseline up to Week 104

  6. Number of participants with neutralizing antibodies

    Time frame: From baseline up to Week 104

07

Study locations

15 sites
  • Investigational Site Number : 3920015
    Ichikawa, Chiba 272-0827, Japan
  • Investigational Site Number : 3920011
    Maebashi, Gunma 371-8511, Japan
  • Investigational Site Number : 3920006
    Sapporo, Hokkaido 060-8543, Japan
  • Investigational Site Number : 3920018
    Kobe, Hyōgo 650-0017, Japan
  • Investigational Site Number : 3920009
    Kanazawa, Ishikawa-ken 920-8641, Japan
  • Investigational Site Number : 3920007
    Yahaba, Iwate 028-3695, Japan
  • Investigational Site Number : 3920019
    Yokohama, Kanagawa 222-0036, Japan
  • Investigational Site Number : 3920001
    Iruma, Saitama 350-0495, Japan
  • Investigational Site Number : 3920010
    Chūō, Yamanashi 409-3898, Japan
  • Investigational Site Number : 3920017
    Fukuoka, 812-0025, Japan
  • Investigational Site Number : 3920016
    Kyoto, 606-8507, Japan
  • Investigational Site Number : 3920014
    Nagasaki, 852-8501, Japan
  • Investigational Site Number : 3920004
    Osaka, 545-8586, Japan
  • Investigational Site Number : 3920020
    Tokyo, 101-8309, Japan
  • Investigational Site Number : 3920003
    Tokyo, 162-8666, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2028, 31 months after the start.

Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 31 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 24, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Mar 6, 2028
CompletionEst.
Mar 6, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 9, 2026
Sites
6 sites added, 2 sites removed. 4 sites changed recruiting status (4 now active, not recruiting)
Show 4 sites
  • Investigational Site Number : 3920018 · Kobe, JapanRecruiting→Active, not recruiting
  • Investigational Site Number : 3920001 · Iruma, JapanRecruiting→Active, not recruiting
  • Investigational Site Number : 3920010 · Chūō, JapanRecruiting→Active, not recruiting
  • Investigational Site Number : 3920016 · Kyoto, JapanRecruiting→Active, not recruiting
Show 6 added (6 Japan)
  • Investigational Site Number : 3920014 · Nagasaki, Japan
  • Investigational Site Number : 3920003 · Tokyo, Japan
  • Investigational Site Number : 3920015 · Ichikawa, Japan
  • Investigational Site Number : 3920011 · Maebashi, Japan
  • Investigational Site Number : 3920009 · Kanazawa, Japan
  • Investigational Site Number : 3920007 · Yahaba, Japan
Show 2 removed
  • Investigational Site Number : 3920015 · Ichikawa, Japan
  • Investigational Site Number : 3920007 · Yahaba, Japan
across 2 updates, Oct 13, 2026 – Nov 9, 2026
Enrollment
10 (estimated)→5 (actual)
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Recruiting→Active, not recruiting
    4 sites added
    Show 4 added (4 Japan)
    • Investigational Site Number : 3920015 · Ichikawa, Japan
    • Investigational Site Number : 3920011 · Maebashi, Japan
    • Investigational Site Number : 3920009 · Kanazawa, Japan
    • Investigational Site Number : 3920007 · Yahaba, Japan
    Enrollment 10 (estimated)→5 (actual)
    + 3 other changes: verification date, contact details and references
  2. Oct 13, 2026
    2 sites added, 2 sites removed. 4 sites changed recruiting status (4 now active, not recruiting)
    Show 4 sites
    • Investigational Site Number : 3920018 · Kobe, JapanRecruiting→Active, not recruiting
    • Investigational Site Number : 3920001 · Iruma, JapanRecruiting→Active, not recruiting
    • Investigational Site Number : 3920010 · Chūō, JapanRecruiting→Active, not recruiting
    • Investigational Site Number : 3920016 · Kyoto, JapanRecruiting→Active, not recruiting
    Show 2 added (2 Japan)
    • Investigational Site Number : 3920014 · Nagasaki, Japan
    • Investigational Site Number : 3920003 · Tokyo, Japan
    Show 2 removed
    • Investigational Site Number : 3920015 · Ichikawa, Japan
    • Investigational Site Number : 3920007 · Yahaba, Japan
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06791291
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Jul 25, 2025
Primary completion
Mar 6, 2028 (estimated)
Completion
Mar 6, 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teplizumab

Start the discussion